|Bid||10.90 x 900|
|Ask||10.91 x 1100|
|Day's Range||10.77 - 11.52|
|52 Week Range||10.10 - 17.09|
|Beta (5Y Monthly)||0.17|
|PE Ratio (TTM)||38.71|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 03, 2021|
|1y Target Est||16.45|
Subscribe to Yahoo Finance Plus to view Fair Value for GRFS
A multinational company that's already one of the largest employers in the Greater Triangle is taking steps toward a huge expansion that's years in the making.
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and the development of innovative diagnostic solutions, today announced that its Procleix Plasmodium Assay has obtained the CE mark, the first for an automated nucleic acid test (NAT) system specifically validated for screening blood donors for malaria.
On top of those pluses, these three companies all have a history of offering above-average dividends, making them solid long-term value bargains. Takeda is a Japanese biopharmaceutical company that focuses on gastroenterology, oncology, neuroscience, and rare diseases. The company's stock is up more than 9% this year, currently trading at just shy of $15.